Provided by Tiger Trade Technology Pte. Ltd.

Avis Budget

117.71
+2.472.14%
Post-market: 117.03-0.6840-0.58%19:54 EDT
Volume:1.29M
Turnover:151.24M
Market Cap:4.16B
PE:-6.56
High:119.85
Open:114.98
Low:112.36
Close:115.24
52wk High:847.70
52wk Low:85.96
Shares:35.32M
Float Shares:14.85M
Volume Ratio:3.20
T/O Rate:8.69%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-17.9408
EPS(LYR):-25.2557
ROE:5800.00%
ROA:2.70%
PB:-1.23
PE(LYR):-4.66

Loading ...

Press Release: CARsgen Therapeutics Announces 2026 Interim Results

Dow Jones
·
Aug 19

Xero Stock And 2 Australian AI Shares Backed By Real World Software Use

Simply Wall St.
·
Aug 18

CARsgen narrows loss and boosts cash on CAR T sales and top-up placing

TIPRANKS
·
Aug 18

3 AI Stocks Riding Real Demand For Cloud And Chip Infrastructure

Simply Wall St.
·
Aug 17

How Investors May Respond To CAR Group (ASX:CAR) FY26 Results And FY27 Growth Guidance

Simply Wall St.
·
Aug 17

AI Stocks To Watch Now As Higher Bond Yields Test Software Leaders

Simply Wall St.
·
Aug 16

AI Stocks To Watch As Chip Demand Lifts Software Growth

Simply Wall St.
·
Aug 15

Avis Budget Group Balances Earnings Strength With Risks

TIPRANKS
·
Aug 15

Beijing's New Policies Drive Cell Therapy Sector with Payment and Approval Reforms, Sparking Industry-wide Value Reassessment

Deep News
·
Aug 14

Fate Therapeutics Initiates Potentially Registrational RECLAIM-LN Clinical Trial of FT819 for the Treatment of Lupus Nephritis

GlobeNewswire
·
Aug 14

Press Release: Tempest Reports Second Quarter 2026 Financial Results and Provides Business Update

Dow Jones
·
Aug 14

Press Release: Caribou Biosciences Reports Second Quarter 2026 Financial Results and Provides Business Update

Dow Jones
·
Aug 14

Tyler Van Buren Reiterates Buy on Allogene, Citing Strong ALPHA3 Trial Momentum and De-Risking Efficacy/Safety Data for Off-the-Shelf CAR-T Cema-cel

TIPRANKS
·
Aug 13

Xero Stock And 2 Australian AI Shares With Real Business Use

Simply Wall St.
·
Aug 13

CAR Group Bulls See EV Adoption as a Tailwind

Dow Jones
·
Aug 13

Morgan Stanley Sticks to Their Buy Rating for CAR Group (WN6)

TIPRANKS
·
Aug 13

Allogene Therapeutics Reports Second Quarter 2026 Financial Results and Business Update

GlobeNewswire
·
Aug 13

Carclo Aligns Senior Executive Incentives With Long-Term Shareholder Returns

TIPRANKS
·
Aug 12

CSPC Pharma Starts Phase 1 Trial of CAR-T Drug for Relapsed, Refractory Lupus

MT Newswires Live
·
Aug 12

Jarden Keeps Their Buy Rating on CAR Group (WN6)

TIPRANKS
·
Aug 12